The peroxisome proliferator activated receptors (PPARs) and their effects on lipid metabolism and adipocyte differentiation

被引:774
|
作者
Schoonjans, K [1 ]
Staels, B [1 ]
Auwerx, J [1 ]
机构
[1] INST PASTEUR, INSERM, U325, LBRE, F-59019 LILLE, FRANCE
来源
BIOCHIMICA ET BIOPHYSICA ACTA-LIPIDS AND LIPID METABOLISM | 1996年 / 1302卷 / 02期
关键词
fatty acid; fibrate; gene expression; hypolipidemic drug; lipid metabolism; nuclear hormone receptor; PPAR; retinoic acid receptor; transcription;
D O I
10.1016/0005-2760(96)00066-5
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The three types of peroxisome proliferator activated receptor (PPAR), α, β (or δ), and γ, each with a specific tissue distribution, compose a subfamily of the nuclear hormone receptor gene family. Although peroxisome proliferators, including fibrates and fatty acids, activate the transcriptional activity of these receptors, only prostaglandin J2 derivatives have been identified as natural ligands of the PPARγ subtype, which also binds thiazolinedione antidiabetic agents with high affinity. Activated PPARs heterodimerize with RXR and alter the transcription of target genes after binding to specific response elements or PPREs, consisting of a direct repeat of the nuclear receptor hexameric DNA core recognition motif spaced by one nucleotide. The different PPARs can be considered key messengers responsible for the translation of nutritional, pharmacological and metabolic stimuli into changes in the expression of genes, more specifically those genes involved in lipid metabolism. PPARα is involved in stimulating β-oxidation of fatty acids. In rodents, a PPAR α-mediated change in the expression of genes involved in fatty acid metabolism lies at the basis of the phenomenon of peroxisome proliferation, a pleiotropic cellular response, mainly limited to liver and kidney and which can lead to hepatocarcinogenesis. In addition to their role in peroxisome proliferation in rodents, PPAR is also involved in the control of HDL cholesterol levels by fibrates and fatty acids in rodents and humans. This effect is, at least partially, based on PPAR-mediated transcriptional regulation of the major HDL apolipoproteins, apo A-I and apo A-II. The hypotriglyceridemic action of fibrates and fatty acids also involves PPARs and can be summarized as follows: (1) an increased lipolysis and clearance of remnant particles, due to changes in LPL and apo C-III levels, (2) a stimulation of cellular fatty acid uptake and their conversion to acyl-CoA derivatives by the induction of FAT, FATP and ACS activity, (3) an induction of fatty acid β-oxidation pathways, (4) a reduction in fatty acid and triglyceride synthesis, and finally (5) a decrease in VLDL production. Hence, both enhanced catabolism of triglyceride-rich particles as well as reduced secretion of VLDL particles are mechanisms that con tribute to the hypolipidemic effect of fibrates and FFAs. Whereas for PPARβ no function so far has been identified, PPARγ triggers adipocyte differentiation by inducing the expression of several genes critical for adipogenesis.
引用
收藏
页码:93 / 109
页数:17
相关论文
共 50 条
  • [31] Minireview: Lipid metabolism, metabolic diseases, and peroxisome proliferator-activated receptors
    Lee, CH
    Olson, P
    Evans, RM
    ENDOCRINOLOGY, 2003, 144 (06) : 2201 - 2207
  • [32] The biology of peroxisome proliferator -: Activated receptors -: Relationship with lipid metabolism and insulin sensitivity
    Ferré, P
    DIABETES, 2004, 53 : S43 - S50
  • [33] Peroxisome Proliferator-Activated Receptors (PPARs) as Potential Inducers of Antineoplastic Effects in CNS Tumors
    Tatenhorst, Lars
    Hahnen, Eric
    Heneka, Michael T.
    PPAR RESEARCH, 2008, 2008
  • [34] Peroxisome Proliferator-Activated Receptors (PPARs), atherothrombosis process and the interventionist cardiologist
    Barrera-Ramírez, CF
    Pineda-Pompa, LR
    Guzmán, CE
    REVISTA DE INVESTIGACION CLINICA-CLINICAL AND TRANSLATIONAL INVESTIGATION, 2004, 56 (05): : 686 - 687
  • [35] Targeting the peroxisome proliferator-activated receptors (PPARs) in spinal cord injury
    Esposito, Emanuela
    Cuzzocrea, Salvatore
    EXPERT OPINION ON THERAPEUTIC TARGETS, 2011, 15 (08) : 943 - 959
  • [36] Peroxisome proliferator-activated receptors (PPARs) in skin health, repair and disease
    Michalik, Liliane
    Wahli, Walter
    BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS, 2007, 1771 (08): : 991 - 998
  • [37] Peroxisome proliferator-activated receptors (PPARs) in obesity and insulin resistance development
    Alemán, G
    Torres, N
    Tovar, AR
    REVISTA DE INVESTIGACION CLINICA-CLINICAL AND TRANSLATIONAL INVESTIGATION, 2004, 56 (03): : 351 - 367
  • [38] The Role of Peroxisome Proliferator-Activated Receptors (PPARs) in Pan-Cancer
    Huang, Runzhi
    Zhang, Jiaqi
    Li, Mingxiao
    Yan, Penghui
    Yin, Huabin
    Zhai, Suna
    Zhu, Xiaolong
    Hu, Peng
    Zhang, Jiaxin
    Huang, Ling
    Li, Man
    Sun, Zehui
    Meng, Tong
    Yang, Daoke
    Huang, Zongqiang
    PPAR RESEARCH, 2020, 2020
  • [39] The role of hepatic peroxisome proliferator-activated receptors (PPARs) in health and disease
    Everett, L
    Galli, A
    Crabb, D
    LIVER, 2000, 20 (03): : 191 - 199
  • [40] PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPARS) IN CHRONIC KIDNEY DISEASE IN AGEING
    Percy, C.
    Brown, L.
    Johnson, D. W.
    Gobe, G.
    NEPHROLOGY, 2008, 13 : A136 - A136